Universidade de São Paulo-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2024

  1. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119

    Journal of Pathology: Clinical Research, Vol. 10, Núm. 3

2023

  1. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study

    European Journal of Cancer, Vol. 195

  2. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10371, pp. 105-117

2022

  1. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 12, pp. 1142-1154

  2. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64

2021

  1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

  2. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

    npj Breast Cancer, Vol. 7, Núm. 1

  3. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

    Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2

2013

  1. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)

    Annals of Oncology, Vol. 24, Núm. 9, pp. 2278-2284

2012

  1. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

    New England Journal of Medicine, Vol. 366, Núm. 2, pp. 109-119